# Junta clínica — PT-pseudo_dcd61cf9b443 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_dcd61cf9b443",
  "pid": "PT-pseudo_dcd61cf9b443",
  "task": 1,
  "psa": 8.3,
  "age": 66,
  "months": 2,
  "pirads": "5",
  "psad": 0.215,
  "psav": 1.64,
  "psap": 7.9,
  "vol": 38.54,
  "dre": "Suspicious",
  "bx": "Positive",
  "cspca": 0.86351734,
  "medhx": "COPD, Chronic kidney disease",
  "meds": "ciprofloxacine",
  "notes": "PSA 8.3 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 39 mL. DRE suspicious. csPCa 0.86.",
  "pmhx": [
    "COPD",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "63 kg",
    "height": "170 cm",
    "bmi": "21.8",
    "bp": "111/75 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (37 pack-yr, quit 2012)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a previously confirmed prostate malignancy alongside a continuously increasing PSA profile."
    },
    {
      "s": "History",
      "t": "Initial evaluation for an elevated PSA occurred in early 2023, leading to active surveillance for a confirmed prostate malignancy. The individual is a 66-year-old retired primary school teacher, currently married but residing independently, with his wife acting as his main appointment liaison. Urinary complaints remain negligible, reflected by an IPSS score of 6, and he sustains a cycling habit of roughly 20 kilometres on two occasions each week. His medical background includes stable COPD and chronic kidney disease with a diminished eGFR, currently addressed via ciprofloxacin therapy. Recent encounters involved vascular surgery for varicose veins alongside a standard gastroenterology surveillance colonoscopy. Outside of urological matters, he experiences occasional mild insomnia but explicitly denies unexplained weight loss, skeletal discomfort, or haematuria. Morning appointments are preferred to align with public transit timetables. He maintains an ex-smoker status, having accumulated 37 pack-years before cessation in 2012."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The gland exhibits asymmetric enlargement, presenting a firm, irregular nodule within the left peripheral zone that aligns with a suspicious clinical impression. General inspection notes a well-nourished male with stable vital signs, absent palpable lymphadenopathy, and no hepatosplenomegaly. Abdominal palpation remains unremarkable, characterized by a soft, non-tender cavity without bladder distension."
    }
  ],
  "occupation": "retired primary school teacher",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Vascular surgery — varicose veins consult",
    "Gastroenterology — surveillance colonoscopy"
  ],
  "alcohol": "33 units / week (heavy)",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 6/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Erasmus MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dcd61cf9b443
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.215 ng/mL²
  - PSA velocity: 1.64 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 38.54 mL
  - Months since last PSA: 2
  - DRE findings: Suspicious (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86351734 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD, Chronic kidney disease
  - Problem list / PMHx: COPD, Chronic kidney disease
  - Current medication: ciprofloxacine
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 39 mL. DRE suspicious. csPCa 0.86.

Vitals: weight 63 kg, height 170 cm, BMI 21.8, BP 111/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (37 pack-yr, quit 2012).

Chief complaint: Assessment of a previously confirmed prostate malignancy alongside a continuously increasing PSA profile.

History: Initial evaluation for an elevated PSA occurred in early 2023, leading to active surveillance for a confirmed prostate malignancy. The individual is a 66-year-old retired primary school teacher, currently married but residing independently, with his wife acting as his main appointment liaison. Urinary complaints remain negligible, reflected by an IPSS score of 6, and he sustains a cycling habit of roughly 20 kilometres on two occasions each week. His medical background includes stable COPD and chronic kidney disease with a diminished eGFR, currently addressed via ciprofloxacin therapy. Recent encounters involved vascular surgery for varicose veins alongside a standard gastroenterology surveillance colonoscopy. Outside of urological matters, he experiences occasional mild insomnia but explicitly denies unexplained weight loss, skeletal discomfort, or haematuria. Morning appointments are preferred to align with public transit timetables. He maintains an ex-smoker status, having accumulated 37 pack-years before cessation in 2012.

Physical examination: DRE: The gland exhibits asymmetric enlargement, presenting a firm, irregular nodule within the left peripheral zone that aligns with a suspicious clinical impression. General inspection notes a well-nourished male with stable vital signs, absent palpable lymphadenopathy, and no hepatosplenomegaly. Abdominal palpation remains unremarkable, characterized by a soft, non-tender cavity without bladder distension.

Patient info: retired primary school teacher; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 33 units / week (heavy); exercise Cycling 2x/week, ~20 km; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult; Gastroenterology — surveillance colonoscopy.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.18 (95% CI 0.18-0.88); among patients it cannot tell apart the outcome was 1.00 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a repeat biopsy on MRI is mandated if the MRI shows a lesion that mandates it to confirm histological progression. It also states that targeted and perilesional biopsy cores should be taken if a confirmatory or repeat biopsy is performed.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the prior positive biopsy status, which is a critical variable in determining the appropriate next step. The guideline does not provide a threshold for when to proceed with a repeat biopsy following a prior positive biopsy.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose does not compare against an earlier study, so the guideline does not support re-sampling based on stability.
Prior biopsy status - The prior biopsy status is a decisive factor because the guideline discusses follow-up after a negative biopsy, which is relevant context here.
PSA trend - The PSA velocity of 1.64 ng/mL/yr is a variable that the guideline makes decisive regarding the need for further investigation.
Prostate volume - The prostate volume of 38.54 mL is a variable that the guideline makes decisive in relation to risk stratification.
DRE finding - The DRE finding of 'Suspicious' is a variable that the guideline makes decisive in relation to the need for further investigation.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on how the mpMRI prose compares to prior studies and how the guideline addresses repeat biopsy after a prior positive biopsy.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares against an earlier study.
  psa_trend (get_psa_trend) -> Confirm the PSA trend information.
  previous_notes (get_previous_notes) -> Establish the management context and prior biopsy findings.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose compare against an earlier study?
  Q2. Does the PSA velocity of 1.64 ng/mL/yr, in conjunction with the prior positive biopsy, mandate a repeat biopsy according to the guideline?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose does not compare against an earlier study, as the report states: "Follow-up on previous malignancy workup."

psa_trend
The PSA trend shows values: {"date": "Jan 2023", "val": 5.8}, {"date": "Jan 2024", "val": 3.7}, {"date": "Jan 2025", "val": 8.3}.

previous_notes
The previous notes establish the management context and prior biopsy findings, noting a prior PSA of "7.9 ng/mL" in January 2024 and a referral for specialized evaluation.

WHAT I DID NOT OPEN
laboratory_results, because the moderator stated they were dropped without naming a specific question that justified them.

WHAT THIS SUPPORTS
FOR sampling this patient now
The PSA trend shows a significant rise from 3.7 ng/mL in Jan 2024 to 8.3 ng/mL in Jan 2025.
The mpMRI report identifies a PI-RADS 5 lesion with high csPCa predicted probability of 0.86351734.

AGAINST sampling this patient now
The EXPERT-COHORT noted that the prior positive biopsy means the panel cannot settle the decision.

WHERE THIS LEANS
The rising PSA trend and the high-risk MRI finding suggest a need for further action, but the prior positive biopsy complicates the decision.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 by stating the mpMRI prose does not compare against an earlier study, and Q2 is not answered by any intervention.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence, specifically the rising PSA trend and the high-risk MRI finding, aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY, whereas the EXPERT-COHORT suggests deferral due to the prior positive biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose compare against an earlier study? Answered by the REGISTRAR, who stated it does not compare against an earlier study.
Q2. Does the PSA velocity of 1.64 ng/mL/yr, in conjunction with the prior positive biopsy, mandate a repeat biopsy according to the guideline? Not answered; the EAU guideline specialist noted that the guideline does not provide a threshold for this specific scenario.

WHAT CARRIES WEIGHT, AND WHY
The relevant variables are the PSA trend, which shows a significant rise, indicating progression risk; the PI-RADS 5 finding, which indicates high local risk; and the prior positive biopsy, which complicates the decision by suggesting the need for a different pathway. The guideline does not support the leaning towards biopsy because it lacks a clear instruction for repeat biopsy after a prior positive result.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, leaning towards the EXPERT-COHORT's implication that the panel cannot settle the decision, but acknowledging the guideline's lack of specific instruction for this exact scenario.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Deferral is appropriate because the patient has a prior positive biopsy, meaning the diagnosis is already established, and the mpMRI prose does not provide a new finding to change management. The rising PSA trend and PI-RADS 5 finding are expected in a known cancer, and the guideline lacks instruction for repeat biopsy after a prior positive result. Therefore, no new biopsy is indicated at this time.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
